Pulmonary toxicity during chemotherapy with etopiside and carboplatin Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? Source: Eur Respir J, 51 (1) 1701737; 10.1183/13993003.01737-2017 Year: 2018
Effects of prednisolone and imatinib mesylate on inflammation and fibrosis in amiodarone-induced pulmonary toxicity in rats Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Gemcitabine induced pulmonary toxicity in a single patient: case report Source: Eur Respir J 2006; 28: Suppl. 50, 753s Year: 2006
Therapeutic effectiveness of early and late surfactant-BL administration in bleomycine induced injury of lung in rats Source: Eur Respir J 2003; 22: Suppl. 45, 532s Year: 2003
Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy Source: Eur Respir J 2001; 18: 243-245 Year: 2001
Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001
Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Lung disease induced by novel chemotherapeutic agents and biomolecules Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006
The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017
Predictors of bleomycin toxicity Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010
The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Cisplatin and docetaxel induction chemotherapy results Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
The loss of pulmonary barrier function as a result of application of anticancer agents paclitaxel, 2-methoxyestradiol, and their combination Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010
A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006
Multicentre phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited stage small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 394s Year: 2001
Combination chemotherapy with gemcitabine using isolated lung perfusion for the treatment of lung metastases Source: Eur Respir J 2004; 24: Suppl. 48, 42s Year: 2004
Antituberculosis chemotherapy toxicity reduction Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Pulmonary toxicity Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019
Survival and respiratory effects in NSCLC patients after treatment with inhaled carboplatin Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010